インスリン市場：薬剤、タイプ、用途別-2024-2030年の世界予測

インスリン市場規模は2023年に436億4,000万米ドルと推定され、2024年には467億6,000万米ドルに達し、CAGR 7.63%で2030年には730億3,000万米ドルに達すると予測されます。

インスリン市場には、世界中で数百万人が罹患している慢性代謝性疾患である糖尿病の治療に使用される様々なインスリンタイプの生産、流通、消費が含まれます。インスリンの主な用途は、自然なインスリンの生産が不足している1型糖尿病患者や、インスリンの放出が不十分または不足した2型糖尿病患者の血糖値をコントロールすることです。この市場には、ヒト型インスリン、速効型や長時間作用型などの最新型インスリン、バイオシミラーインスリンが含まれます。人口の高齢化による糖尿病有病率の増加、ヘルスケアサービスへのアクセスの改善、糖尿病管理に関する意識の向上、インスリンの使用と生産を拡大するための政府の支援イニシアティブ。一方、インスリンの高価格と複雑な規制環境が市場成長の妨げとなっています。しかし、バイオテクノロジーの進歩により、新規のインスリンが開発され、承認率が上昇していることから、今後数年間は市場の成長が促進されると予想されます。

医薬品生物学的製剤は、安全性、有効性、革新的な特徴を有するため、大きな利用が見込まれる

生物学的製剤（インスリン）とは、バクテリアや酵母細胞などの生体内で組換えDNA技術を用いて合成された天然由来のインスリンです。これらのインスリンはヒトのインスリンと化学的に同一であり、身体の正常なインスリン反応を忠実に模倣しています。さらに、生物学的なインスリンは、その正確な分子構造と機能により、血糖値のコントロールに高い効果を示します。バイオシミラーインスリンは、過去に承認を受けた生物学的製剤インスリンと類似しており、安全性、純度、効力に関して参照製剤と臨床的に重要な差異はありません。これらのインスリンは、バイオシミラーの製造工程に関連する研究開発コストが削減されているため、先発品よりも低価格であることが多いです。バイオシミラーインスリンが好まれるのは、先発品の生物学的製剤インスリンと比較して費用対効果が高いからです。バイオシミラーインスリンは、同等の有効性と安全性プロファイルを提供するため、ヘルスケアシステムは患者の転帰を損なうことなく費用を節約することができます。生物学的製剤とバイオシミラーインスリンのどちらを選択するかは、患者の反応、アレルギー反応の可能性、医療システムの費用負担の問題、入手のしやすさなどに左右されます。両分野の継続的な進歩により、より安全で効果的な治療オプションが提供されるとともに、世界中のヘルスケアシステムが直面するコスト課題に対処することで、糖尿病治療のさらなる向上が期待されます。

タイプ長時間作用型インスリンは、長時間にわたって基礎作用をカバーします。

中間作用型のインスリンは、長期間にわたってインスリンを安定的に放出するように設計されています。より安定した、より長時間のインスリン効果を必要とする糖尿病患者は、中間作用型のインスリンを好むかもしれません。長時間作用型のインスリンは、最大24時間以上持続する血糖コントロールを提供し、通常1日1回投与され、最適なグルコース管理のためにしばしば他の剤形のインスリンと併用されます。プレミックスインスリンは中間作用型と短時間作用型または速効型インスリンを組み合わせ、即効性と持続性の両方の血糖コントロールを提供します。速効型インスリンは、投与後すぐに効果を発揮し、食前の血糖をコントロールするため、高血糖を速やかに改善したい患者様に最適です。短時間作用型のインスリンは、一般的に通常のインスリンと呼ばれ、投与後1時間以内に血糖をコントロールします。中間作用型のインスリンに比べ、即効性はあるが作用時間が短いことを必要とする患者に適しています。

用途i型糖尿病患者がインスリンを多用する場合、常に監視し、適時に投与する必要があります。

I型糖尿病は、インスリン依存性または若年性糖尿病とも呼ばれ、膵臓が十分なインスリンを産生できない慢性疾患です。その結果、i型糖尿病患者は血糖値を調節するために外因性のインスリンを必要とします。このグループでは、食事中の生理的なインスリン放出を模倣するために、吸収が早く、作用時間がピークに達する速効性のインスリンが必要とされています。II型糖尿病は最も一般的な糖尿病であり、インスリンの作用に対する抵抗性またはこのホルモンの不十分な産生を特徴とします。型糖尿病患者は、疾患の進行に応じて、経口薬から非インスリン注射薬またはインスリン注射まで、様々な治療が必要となります。このグループには、24時間にわたって安定した効果を発揮する長時間作用型の基礎インスリンと、食事時の血糖コントロールに必要であればボーラス注射を追加することが、必要性に応じて選択されます。どちらのタイプの糖尿病でも効果的な血糖管理戦略が必要であるが、個々のニーズに基づいた特定のインスリンや補助療法の嗜好を考慮すると、違いが生じる。

地域別の洞察

南北アメリカ地域では、主要プレイヤーの存在、より良いヘルスケアインフラ、疾病管理に関する意識の高まりにより、北米がインスリン市場を独占しています。糖尿病の早期診断・治療に対する政府の取り組みなどの要因も、この成長に大きく寄与しています。南米では急速に高齢化が進む中、糖尿病患者が増加しています。メキシコやブラジルのような国々は、糖尿病を含む非感染性疾患の予防と管理に焦点を当てた国家政策を導入しており、同地域の市場拡大をさらに加速させています。アジア太平洋地域は、ヘルスケア・インフラと製品供給力の向上により、インスリンの主要市場として急速に台頭しています。さらに、APAC諸国は費用対効果の高いインスリン製品を製造するため、研究開発に多額の投資を行っています。近年、この地域ではインスリンペンやポンプなどの高度なインスリンデリバリーシステムの採用が急増しています。糖尿病管理の選択肢を知る人が増えるにつれ、APAC諸国ではインスリンと関連機器の需要が増加すると予測されています。西欧のインスリン市場は、医療インフラが整備され、革新的なインスリン治療へのアクセスが向上していることから急成長しています。中東・アフリカ地域では、ヘルスケアインフラの改善や政府・国際機関の取り組みがインスリン市場の成長を支えています。南アフリカなどの国々では、健康促進戦略を通じて糖尿病を含む非感染性疾患と闘う政策を導入しており、この分野の市場成長を促進する可能性があります。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは、インスリン市場の評価において極めて重要です。事業戦略や製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析は、インスリン市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています：

1.市場の浸透度：主要企業が提供する市場に関する包括的な情報を提示しています。

2.市場の開拓度：有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3.市場の多様化：新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4.競合の評価と情報：市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力について徹底的な評価を行います。

5.製品開発およびイノベーション：将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています：

1.インスリン市場の市場規模および予測は？

2.インスリン市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か？

3.インスリン市場の技術動向と規制枠組みは？

4.インスリン市場における主要ベンダーの市場シェアは？

5.インスリン市場への参入に適した形態や戦略的手段は？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 高齢化人口の増加に伴い糖尿病と肥満の発生率が上昇
    • インスリン配信システムの急速な発展
    • 先進国におけるインスリン製品に対する有利な償還ポリシー
  • 抑制要因
    • インスリン薬に関連する高コスト
  • 機会
    • インスリン開発のためのR&D活動への潜在的投資
    • 互換性のあるバイオシミラーインスリン製品の承認増加
  • 課題
    • 複雑な規制状況と患者の治療計画遵守に関する問題
• 市場セグメンテーション分析
  • 医薬品：安全性、有効性、革新的な特徴を有する生物学的医薬品の重要な使用
  • タイプ：長時間作用型インスリンは、長期間にわたって基礎インスリンをカバーします。
  • 応用：1型糖尿病患者によるインスリンの広範な使用には、インスリンの継続的な監視と適時の投与が必要です。
• 市場動向分析
  • 確立されたヘルスケアインフラと手頃な価格の製品の開発が、南北南北アメリカ全体の市場成長を支えています。
  • APAC地域でインスリンのアクセシビリティと使用率を高めるための政府の支援
  • EMEA地域におけるインスリンの研究開発活動と償還ポリシーの利用可能性
• ロシア・ウクライナ紛争の累積的影響
• 高インフレの累積的影響
• ポーターのファイブフォース分析
• バリューチェーンとクリティカルパス分析
• 規制枠組みの分析

第6章 インスリン市場薬物別

• 生物学的
• バイオシミラー

第7章 インスリン市場：タイプ別

• 中間作用型インスリン
• 長時間作用型インスリン
• プレミックスインスリン
• 即効性インスリン
• 短時間作用型インスリン

第8章 インスリン市場：用途別

• 1型糖尿病
• 2型糖尿病

第9章 南北アメリカのインスリン市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域のインスリン市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカのインスリン市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス、2023
• 競合シナリオ分析
  • インスリンメーカーのジェネシスがハイデラバードに工場を建設するため5000万～6,000万米ドルを投資
  • ガルフ・ファーマシューティカル・インダストリーズ「ジュルファー」がサンシャイン・レイク・ファーマと画期的な契約を締結し、MENAにおけるバイオシミラー製造のパイオニアとなる
  • サノフィ、インドで長期作用型新薬を発売
  • カリフォルニアと製薬会社が提携して手頃な価格のインスリンを生産
  • ノボノルディスク、インドの患者向けに週1回のインスリン療法を開始
  • ADOCIA、パートナーのTonghua Dongbaoと共同でバイオシャペロン・リスプロの第1相試験の成功を発表
  • グレンマークがインドで2型糖尿病および高耐性薬を発売、株価急騰
  • リリーとEVAファーマ、アフリカにおける手頃な価格のインスリンへの持続的なアクセス強化に向けた提携を発表
  • ノボノルディスク、患者の購入オプションを拡大するため、トレシーバアナログのブランドなし生物学的製剤インスリンを発売
  • オプタムとサノフィ、無保険者向けの低コストのインスリンで提携

第13章 競合ポートフォリオ

• 主要企業プロファイル
• 主要製品ポートフォリオ

LIST OF FIGURES

• FIGURE 1. INSULIN MARKET RESEARCH PROCESS
• FIGURE 2. INSULIN MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL INSULIN MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL INSULIN MARKET SIZE, BY REGION, 2023 VS 2030 (%)
• FIGURE 5. GLOBAL INSULIN MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. INSULIN MARKET DYNAMICS
• FIGURE 7. GLOBAL INSULIN MARKET SIZE, BY DRUG, 2023 VS 2030 (%)
• FIGURE 8. GLOBAL INSULIN MARKET SIZE, BY DRUG, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 9. GLOBAL INSULIN MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 10. GLOBAL INSULIN MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 11. GLOBAL INSULIN MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 12. GLOBAL INSULIN MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 13. AMERICAS INSULIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 14. AMERICAS INSULIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 15. UNITED STATES INSULIN MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 16. UNITED STATES INSULIN MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 17. ASIA-PACIFIC INSULIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 18. ASIA-PACIFIC INSULIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA INSULIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA INSULIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 21. INSULIN MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 22. INSULIN MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. INSULIN MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL INSULIN MARKET SIZE, 2018-2023 (USD MILLION)
• TABLE 4. GLOBAL INSULIN MARKET SIZE, 2024-2030 (USD MILLION)
• TABLE 5. GLOBAL INSULIN MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 6. GLOBAL INSULIN MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 7. GLOBAL INSULIN MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
• TABLE 8. GLOBAL INSULIN MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
• TABLE 9. GLOBAL INSULIN MARKET SIZE, BY BIOLOGIC, BY REGION, 2018-2023 (USD MILLION)
• TABLE 10. GLOBAL INSULIN MARKET SIZE, BY BIOLOGIC, BY REGION, 2024-2030 (USD MILLION)
• TABLE 11. GLOBAL INSULIN MARKET SIZE, BY BIOSIMILAR, BY REGION, 2018-2023 (USD MILLION)
• TABLE 12. GLOBAL INSULIN MARKET SIZE, BY BIOSIMILAR, BY REGION, 2024-2030 (USD MILLION)
• TABLE 13. GLOBAL INSULIN MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 14. GLOBAL INSULIN MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 15. GLOBAL INSULIN MARKET SIZE, BY INTERMEDIATE-ACTING INSULIN, BY REGION, 2018-2023 (USD MILLION)
• TABLE 16. GLOBAL INSULIN MARKET SIZE, BY INTERMEDIATE-ACTING INSULIN, BY REGION, 2024-2030 (USD MILLION)
• TABLE 17. GLOBAL INSULIN MARKET SIZE, BY LONG-ACTING INSULIN, BY REGION, 2018-2023 (USD MILLION)
• TABLE 18. GLOBAL INSULIN MARKET SIZE, BY LONG-ACTING INSULIN, BY REGION, 2024-2030 (USD MILLION)
• TABLE 19. GLOBAL INSULIN MARKET SIZE, BY PREMIXED INSULIN, BY REGION, 2018-2023 (USD MILLION)
• TABLE 20. GLOBAL INSULIN MARKET SIZE, BY PREMIXED INSULIN, BY REGION, 2024-2030 (USD MILLION)
• TABLE 21. GLOBAL INSULIN MARKET SIZE, BY RAPID-ACTING INSULIN, BY REGION, 2018-2023 (USD MILLION)
• TABLE 22. GLOBAL INSULIN MARKET SIZE, BY RAPID-ACTING INSULIN, BY REGION, 2024-2030 (USD MILLION)
• TABLE 23. GLOBAL INSULIN MARKET SIZE, BY SHORT-ACTING INSULIN, BY REGION, 2018-2023 (USD MILLION)
• TABLE 24. GLOBAL INSULIN MARKET SIZE, BY SHORT-ACTING INSULIN, BY REGION, 2024-2030 (USD MILLION)
• TABLE 25. GLOBAL INSULIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 26. GLOBAL INSULIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 27. GLOBAL INSULIN MARKET SIZE, BY TYPE I DIABETES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 28. GLOBAL INSULIN MARKET SIZE, BY TYPE I DIABETES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 29. GLOBAL INSULIN MARKET SIZE, BY TYPE II DIABETES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 30. GLOBAL INSULIN MARKET SIZE, BY TYPE II DIABETES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 31. AMERICAS INSULIN MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
• TABLE 32. AMERICAS INSULIN MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
• TABLE 33. AMERICAS INSULIN MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 34. AMERICAS INSULIN MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 35. AMERICAS INSULIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 36. AMERICAS INSULIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 37. AMERICAS INSULIN MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 38. AMERICAS INSULIN MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 39. ARGENTINA INSULIN MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
• TABLE 40. ARGENTINA INSULIN MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
• TABLE 41. ARGENTINA INSULIN MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 42. ARGENTINA INSULIN MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 43. ARGENTINA INSULIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 44. ARGENTINA INSULIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 45. BRAZIL INSULIN MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
• TABLE 46. BRAZIL INSULIN MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
• TABLE 47. BRAZIL INSULIN MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 48. BRAZIL INSULIN MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 49. BRAZIL INSULIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 50. BRAZIL INSULIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 51. CANADA INSULIN MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
• TABLE 52. CANADA INSULIN MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
• TABLE 53. CANADA INSULIN MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 54. CANADA INSULIN MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 55. CANADA INSULIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 56. CANADA INSULIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 57. MEXICO INSULIN MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
• TABLE 58. MEXICO INSULIN MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
• TABLE 59. MEXICO INSULIN MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 60. MEXICO INSULIN MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 61. MEXICO INSULIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 62. MEXICO INSULIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 63. UNITED STATES INSULIN MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
• TABLE 64. UNITED STATES INSULIN MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
• TABLE 65. UNITED STATES INSULIN MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 66. UNITED STATES INSULIN MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 67. UNITED STATES INSULIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 68. UNITED STATES INSULIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 69. UNITED STATES INSULIN MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
• TABLE 70. UNITED STATES INSULIN MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
• TABLE 71. ASIA-PACIFIC INSULIN MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
• TABLE 72. ASIA-PACIFIC INSULIN MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
• TABLE 73. ASIA-PACIFIC INSULIN MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 74. ASIA-PACIFIC INSULIN MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 75. ASIA-PACIFIC INSULIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 76. ASIA-PACIFIC INSULIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 77. ASIA-PACIFIC INSULIN MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 78. ASIA-PACIFIC INSULIN MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 79. AUSTRALIA INSULIN MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
• TABLE 80. AUSTRALIA INSULIN MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
• TABLE 81. AUSTRALIA INSULIN MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 82. AUSTRALIA INSULIN MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 83. AUSTRALIA INSULIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 84. AUSTRALIA INSULIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 85. CHINA INSULIN MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
• TABLE 86. CHINA INSULIN MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
• TABLE 87. CHINA INSULIN MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 88. CHINA INSULIN MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 89. CHINA INSULIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 90. CHINA INSULIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 91. INDIA INSULIN MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
• TABLE 92. INDIA INSULIN MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
• TABLE 93. INDIA INSULIN MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 94. INDIA INSULIN MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 95. INDIA INSULIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 96. INDIA INSULIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 97. INDONESIA INSULIN MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
• TABLE 98. INDONESIA INSULIN MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
• TABLE 99. INDONESIA INSULIN MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 100. INDONESIA INSULIN MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 101. INDONESIA INSULIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 102. INDONESIA INSULIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 103. JAPAN INSULIN MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
• TABLE 104. JAPAN INSULIN MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
• TABLE 105. JAPAN INSULIN MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 106. JAPAN INSULIN MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 107. JAPAN INSULIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 108. JAPAN INSULIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 109. MALAYSIA INSULIN MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
• TABLE 110. MALAYSIA INSULIN MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
• TABLE 111. MALAYSIA INSULIN MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 112. MALAYSIA INSULIN MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 113. MALAYSIA INSULIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 114. MALAYSIA INSULIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 115. PHILIPPINES INSULIN MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
• TABLE 116. PHILIPPINES INSULIN MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
• TABLE 117. PHILIPPINES INSULIN MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 118. PHILIPPINES INSULIN MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 119. PHILIPPINES INSULIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 120. PHILIPPINES INSULIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 121. SINGAPORE INSULIN MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
• TABLE 122. SINGAPORE INSULIN MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
• TABLE 123. SINGAPORE INSULIN MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 124. SINGAPORE INSULIN MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 125. SINGAPORE INSULIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 126. SINGAPORE INSULIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 127. SOUTH KOREA INSULIN MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
• TABLE 128. SOUTH KOREA INSULIN MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
• TABLE 129. SOUTH KOREA INSULIN MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 130. SOUTH KOREA INSULIN MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 131. SOUTH KOREA INSULIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 132. SOUTH KOREA INSULIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 133. TAIWAN INSULIN MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
• TABLE 134. TAIWAN INSULIN MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
• TABLE 135. TAIWAN INSULIN MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 136. TAIWAN INSULIN MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 137. TAIWAN INSULIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 138. TAIWAN INSULIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 139. THAILAND INSULIN MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
• TABLE 140. THAILAND INSULIN MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
• TABLE 141. THAILAND INSULIN MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 142. THAILAND INSULIN MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 143. THAILAND INSULIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 144. THAILAND INSULIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 145. VIETNAM INSULIN MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
• TABLE 146. VIETNAM INSULIN MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
• TABLE 147. VIETNAM INSULIN MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 148. VIETNAM INSULIN MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 149. VIETNAM INSULIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 150. VIETNAM INSULIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 151. EUROPE, MIDDLE EAST & AFRICA INSULIN MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
• TABLE 152. EUROPE, MIDDLE EAST & AFRICA INSULIN MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
• TABLE 153. EUROPE, MIDDLE EAST & AFRICA INSULIN MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 154. EUROPE, MIDDLE EAST & AFRICA INSULIN MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 155. EUROPE, MIDDLE EAST & AFRICA INSULIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 156. EUROPE, MIDDLE EAST & AFRICA INSULIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 157. EUROPE, MIDDLE EAST & AFRICA INSULIN MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 158. EUROPE, MIDDLE EAST & AFRICA INSULIN MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 159. DENMARK INSULIN MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
• TABLE 160. DENMARK INSULIN MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
• TABLE 161. DENMARK INSULIN MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 162. DENMARK INSULIN MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 163. DENMARK INSULIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 164. DENMARK INSULIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 165. EGYPT INSULIN MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
• TABLE 166. EGYPT INSULIN MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
• TABLE 167. EGYPT INSULIN MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 168. EGYPT INSULIN MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 169. EGYPT INSULIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 170. EGYPT INSULIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 171. FINLAND INSULIN MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
• TABLE 172. FINLAND INSULIN MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
• TABLE 173. FINLAND INSULIN MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 174. FINLAND INSULIN MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 175. FINLAND INSULIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 176. FINLAND INSULIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 177. FRANCE INSULIN MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
• TABLE 178. FRANCE INSULIN MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
• TABLE 179. FRANCE INSULIN MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 180. FRANCE INSULIN MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 181. FRANCE INSULIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 182. FRANCE INSULIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 183. GERMANY INSULIN MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
• TABLE 184. GERMANY INSULIN MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
• TABLE 185. GERMANY INSULIN MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 186. GERMANY INSULIN MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 187. GERMANY INSULIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 188. GERMANY INSULIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 189. ISRAEL INSULIN MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
• TABLE 190. ISRAEL INSULIN MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
• TABLE 191. ISRAEL INSULIN MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 192. ISRAEL INSULIN MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 193. ISRAEL INSULIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 194. ISRAEL INSULIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 195. ITALY INSULIN MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
• TABLE 196. ITALY INSULIN MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
• TABLE 197. ITALY INSULIN MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 198. ITALY INSULIN MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 199. ITALY INSULIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 200. ITALY INSULIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 201. NETHERLANDS INSULIN MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
• TABLE 202. NETHERLANDS INSULIN MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
• TABLE 203. NETHERLANDS INSULIN MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 204. NETHERLANDS INSULIN MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 205. NETHERLANDS INSULIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 206. NETHERLANDS INSULIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 207. NIGERIA INSULIN MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
• TABLE 208. NIGERIA INSULIN MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
• TABLE 209. NIGERIA INSULIN MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 210. NIGERIA INSULIN MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 211. NIGERIA INSULIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 212. NIGERIA INSULIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 213. NORWAY INSULIN MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
• TABLE 214. NORWAY INSULIN MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
• TABLE 215. NORWAY INSULIN MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 216. NORWAY INSULIN MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 217. NORWAY INSULIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 218. NORWAY INSULIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 219. POLAND INSULIN MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
• TABLE 220. POLAND INSULIN MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
• TABLE 221. POLAND INSULIN MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 222. POLAND INSULIN MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 223. POLAND INSULIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 224. POLAND INSULIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 225. QATAR INSULIN MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
• TABLE 226. QATAR INSULIN MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
• TABLE 227. QATAR INSULIN MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 228. QATAR INSULIN MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 229. QATAR INSULIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 230. QATAR INSULIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 231. RUSSIA INSULIN MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
• TABLE 232. RUSSIA INSULIN MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
• TABLE 233. RUSSIA INSULIN MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 234. RUSSIA INSULIN MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 235. RUSSIA INSULIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 236. RUSSIA INSULIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 237. SAUDI ARABIA INSULIN MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
• TABLE 238. SAUDI ARABIA INSULIN MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
• TABLE 239. SAUDI ARABIA INSULIN MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 240. SAUDI ARABIA INSULIN MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 241. SAUDI ARABIA INSULIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 242. SAUDI ARABIA INSULIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 243. SOUTH AFRICA INSULIN MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
• TABLE 244. SOUTH AFRICA INSULIN MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
• TABLE 245. SOUTH AFRICA INSULIN MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 246. SOUTH AFRICA INSULIN MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 247. SOUTH AFRICA INSULIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 248. SOUTH AFRICA INSULIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 249. SPAIN INSULIN MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
• TABLE 250. SPAIN INSULIN MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
• TABLE 251. SPAIN INSULIN MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 252. SPAIN INSULIN MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 253. SPAIN INSULIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 254. SPAIN INSULIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 255. SWEDEN INSULIN MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
• TABLE 256. SWEDEN INSULIN MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
• TABLE 257. SWEDEN INSULIN MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 258. SWEDEN INSULIN MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 259. SWEDEN INSULIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 260. SWEDEN INSULIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 261. SWITZERLAND INSULIN MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
• TABLE 262. SWITZERLAND INSULIN MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
• TABLE 263. SWITZERLAND INSULIN MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 264. SWITZERLAND INSULIN MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 265. SWITZERLAND INSULIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 266. SWITZERLAND INSULIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 267. TURKEY INSULIN MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
• TABLE 268. TURKEY INSULIN MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
• TABLE 269. TURKEY INSULIN MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 270. TURKEY INSULIN MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 271. TURKEY INSULIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 272. TURKEY INSULIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 273. UNITED ARAB EMIRATES INSULIN MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
• TABLE 274. UNITED ARAB EMIRATES INSULIN MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
• TABLE 275. UNITED ARAB EMIRATES INSULIN MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 276. UNITED ARAB EMIRATES INSULIN MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 277. UNITED ARAB EMIRATES INSULIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 278. UNITED ARAB EMIRATES INSULIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 279. UNITED KINGDOM INSULIN MARKET SIZE, BY DRUG, 2018-2023 (USD MILLION)
• TABLE 280. UNITED KINGDOM INSULIN MARKET SIZE, BY DRUG, 2024-2030 (USD MILLION)
• TABLE 281. UNITED KINGDOM INSULIN MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
• TABLE 282. UNITED KINGDOM INSULIN MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
• TABLE 283. UNITED KINGDOM INSULIN MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 284. UNITED KINGDOM INSULIN MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 285. INSULIN MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 286. INSULIN MARKET, FPNV POSITIONING MATRIX, 2023

[199 Pages Report] The Insulin Market size was estimated at USD 43.64 billion in 2023 and expected to reach USD 46.76 billion in 2024, at a CAGR 7.63% to reach USD 73.03 billion by 2030.

The insulin market encompasses the production, distribution, and consumption of various insulin types used to treat diabetes mellitus, a chronic metabolic disorder affecting millions worldwide. The primary application of insulin is to control blood sugar levels in patients with type 1 diabetes who lack natural insulin production and those with type 2 diabetes who have developed insufficient or insufficient insulin release. The scope of this market includes human insulin, modern insulins such as rapid-acting and long-acting, and biosimilar insulins. Increasing prevalence of diabetes due to aging populations, improved access to healthcare services, increased awareness about diabetes management, and supportive government initiatives to expand the use and production of insulin. On the other hand, the high cost of insulin and the complex regulatory environment hinder the market growth. However, advancements in biotechnology, which have led to development of novel insulins and increasing approval rates, are expected to proliferate the market growth in the coming years.

Drug: Significant use of biologic drugs due to having safety, efficacy, and innovative features

Biologic insulin is naturally occurring insulin synthesized using recombinant DNA technology in living organisms, such as bacteria or yeast cells. These insulins are chemically identical to human insulin and closely mimic the body's normal insulin response. Additionally, biological insulins demonstrate high efficacy in controlling blood sugar levels due to their precise molecular structure and function. Biosimilar insulins are similar to biologic insulins that have previously received approval and have no clinically significant variations from their reference products regarding safety, purity, or potency. These insulins are often more affordable than their branded counterparts due to reduced research and development costs associated with the biosimilars' production process. Preference for biosimilar insulin arises from its cost-effectiveness compared to branded biologic insulin options. It provides comparable efficacy and safety profiles, allowing healthcare systems to save on expenses without compromising patient outcomes. The choice between biologic or biosimilar insulin depends on patient response, potential allergic reactions, healthcare system affordability concerns, and accessibility. Continued advancements in both segments are expected to further enhance diabetes care by providing safer and more effective treatment options while addressing the cost challenges healthcare systems worldwide face.

Type: Long-acting insulins provide basal coverage for an extended duration

Intermediate-acting insulin is designed to provide a steady insulin release over an extended period. People with diabetes who require a more stable and longer-lasting insulin effect may prefer intermediate-acting insulin. Long-acting insulin offers prolonged blood sugar control, lasting up to 24 hours or more, usually administered once daily, and is often combined with other forms of insulin for optimal glucose management. Premixed insulin combines intermediate-acting and short- or rapid-acting insulins, offering both immediate and sustained blood sugar control. Rapid-acting insulin works quickly after administration, controlling blood sugar before a meal, which is ideal for patients who need rapid correction of high blood glucose levels. Short-acting insulin, commonly known as regular insulin, controls blood sugar less than an hour after administration. It is suitable for patients who require a fast onset but shorter duration of action than intermediate-acting insulins.

Application: Extensive use of insulin by type I diabetic patients requires constant monitoring and timely administration of insulin

Type I diabetes, also called insulin-dependent or juvenile diabetes, is a chronic disease described by the incapacity of the pancreas to produce adequate insulin. As a result, patients with Type I diabetes require exogenous insulin to regulate their blood glucose levels. The need-based preference for this group is fast-acting insulins that provide rapid absorption and peak action time to mimic physiological insulin release during meals. Type II diabetes is the most common form of diabetes, characterized by resistance to the effects of insulin or insufficient production of this hormone. Patients with Type II diabetes may require various treatments ranging from oral medications to non-insulin injectable drugs or insulin injections, depending on disease progression. The need-based preference for this group includes long-acting basal insulins providing steady coverage over 24 hours and additional bolus injections if required for mealtime blood sugar control. Although both types of diabetes necessitate effective blood glucose management strategies, distinctions arise when considering the preferences for specific insulins or adjunct therapies based on individual needs.

Regional Insights

In the Americas region, North America dominates the insulin market due to the presence of key players, better healthcare infrastructure, and increased awareness regarding disease management. Factors such as government initiatives for early diagnosis and treatment of diabetes are also contributing significantly to this growth. South America is witnessing rising cases of diabetes amidst its rapidly aging population. Countries such as Mexico and Brazil have introduced national policies focusing on preventing and controlling non-communicable diseases, including diabetes, further accelerating market expansion in the region. The Asia-Pacific region is fast emerging as a major market for insulin due to its improvements in healthcare infrastructure and product availability. Furthermore, APAC countries have invested heavily in research and development to produce cost-effective insulin products. In recent years, there has been a surge in the adoption of advanced insulin delivery systems, such as insulin pens and pumps, in the region. As more people become aware of diabetes management options, the demand for insulin and associated devices is projected to increase across APAC countries. Western Europe's insulin market is growing rapidly due to its well-established healthcare infrastructure and increased accessibility to innovative insulin therapies. In the Middle East and Africa region, improving healthcare infrastructure and efforts made by government and international organizations support insulin market growth. Countries such as South Africa are introducing policies to combat non-communicable diseases, including diabetes, through health promotion strategies, which could drive market growth in this area.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Insulin Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Insulin Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Insulin Market, highlighting leading vendors and their innovative profiles. These include ADOCIA, AstraZeneca PLC, Baxter International, Inc., Biocon Limited, Bioton S.A., CardioVends, Eli Lilly and Company, Eva Pharma, GeneSys Biologics, Glenmark Pharmaceuticals Ltd., Gulf Pharmaceutical Industries (Julphar), MannKind Corporation, Merck & Co., Inc., MJ Biopharm Pvt. Ltd., Novartis AG, Novo Nordisk A/S, Oramed Pharmaceuticals Inc., Pfizer Inc., Sanofi Group, Tonghua Dongbao Pharmaceutical Co., Ltd., Viatris Inc., Wockhardt Limited, and Zealand Pharma A/S.

Market Segmentation & Coverage

This research report categorizes the Insulin Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Drug
  • Biologic
  • Biosimilar

• Type
  • Intermediate-acting Insulin
  • Long-acting Insulin
  • Premixed Insulin
  • Rapid-acting Insulin
  • Short-acting Insulin

• Application
  • Type I Diabetes
  • Type II Diabetes

• Region
  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam

• Europe, Middle East & Africa
  • Denmark
  • Egypt
  • Finland
  • France
  • Germany
  • Israel
  • Italy
  • Netherlands
  • Nigeria
  • Norway
  • Poland
  • Qatar
  • Russia
  • Saudi Arabia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Turkey
  • United Arab Emirates
  • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Insulin Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Insulin Market?

3. What are the technology trends and regulatory frameworks in the Insulin Market?

4. What is the market share of the leading vendors in the Insulin Market?

5. Which modes and strategic moves are suitable for entering the Insulin Market?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising incidence of diabetes and obesity with increasing geriatric population
    • 5.1.1.2. Rapid development in insulin delivery systems
    • 5.1.1.3. Favorable reimbursement policies for insulin products in developed countries
  • 5.1.2. Restraints
    • 5.1.2.1. High cost associated with insulin drugs
  • 5.1.3. Opportunities
    • 5.1.3.1. Potential investments in R&D activities for insulin development
    • 5.1.3.2. Rising approvals for interchangeable biosimilar insulin products
  • 5.1.4. Challenges
    • 5.1.4.1. Complex regulatory landscape and problems related to patient adherence to treatment regimens
• 5.2. Market Segmentation Analysis
  • 5.2.1. Drug: Significant use of biologic drugs due to having safety, efficacy, and innovative features
  • 5.2.2. Type: Long-acting insulins provide basal coverage for an extended duration
  • 5.2.3. Application: Extensive use of insulin by type I diabetic patients requires constant monitoring and timely administration of insulin
• 5.3. Market Trend Analysis
  • 5.3.1. Established healthcare infrastructure and development of affordable product have supplemented market growth across the Americas
  • 5.3.2. Government support to increase accessibility and usage of insulin in APAC region
  • 5.3.3. Research & development activities and availability of reimbursement policies for insulin in the EMEA region
• 5.4. Cumulative Impact of Russia-Ukraine Conflict
• 5.5. Cumulative Impact of High Inflation
• 5.6. Porter's Five Forces Analysis
  • 5.6.1. Threat of New Entrants
  • 5.6.2. Threat of Substitutes
  • 5.6.3. Bargaining Power of Customers
  • 5.6.4. Bargaining Power of Suppliers
  • 5.6.5. Industry Rivalry
• 5.7. Value Chain & Critical Path Analysis
• 5.8. Regulatory Framework Analysis

6. Insulin Market, by Drug

• 6.1. Introduction
• 6.2. Biologic
• 6.3. Biosimilar

7. Insulin Market, by Type

• 7.1. Introduction
• 7.2. Intermediate-acting Insulin
• 7.3. Long-acting Insulin
• 7.4. Premixed Insulin
• 7.5. Rapid-acting Insulin
• 7.6. Short-acting Insulin

8. Insulin Market, by Application

• 8.1. Introduction
• 8.2. Type I Diabetes
• 8.3. Type II Diabetes

9. Americas Insulin Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Insulin Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Insulin Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
  • 12.3.1. Insulin Maker GeneSys to Invest USD 50-60 MN to Set Up Plant in Hyderabad
  • 12.3.2. Gulf Pharmaceutical Industries 'Julphar' Signs Landmark Agreement with Sunshine Lake Pharma to Pioneer Insulin Biosimilar Manufacturing in MENA
  • 12.3.3. Sanofi Launches New Long-Acting Insulin Drug in India
  • 12.3.4. California, Drugmaker Partner to Produce Affordable Insulin
  • 12.3.5. Novo Nordisk to Launch Once-a-Week Insulin Regime for Indian Patients
  • 12.3.6. ADOCIA Announces the Successful Phase 1 Study for BioChaperone Lispro with Partner Tonghua Dongbao
  • 12.3.7. Glenmark Launches Type 2 Diabetes and High Insulin Resistance Drug in India; Shares Jump
  • 12.3.8. Lilly and EVA Pharma Announce Collaboration to Enhance Sustainable Access to Affordable Insulin in Africa
  • 12.3.9. Novo Nordisk Launches Unbranded Biologic of Tresiba Analog Insulin to Expand Affordability Options for Patients
  • 12.3.10. Optum, Sanofi Partner on Low Cost Insulin for the Uninsured

13. Competitive Portfolio

• 13.1. Key Company Profiles
• 13.2. Key Product Portfolio